Web Results

caselaw.findlaw.com/ma-supreme-judicial-court/1702954.html

Jun 3, 2015 ... See Kourouvacilis v. General Motors Corp., 410 Mass. 706, 716, 575 N.E.2d 734 (1991); Mass. R. Civ. P. 56(c), as amended, 436 Mass. 1404 (2002). Moreover, “[ w]e exercise de novo review over questions of statutory construction.” Atlanticare Med. Ctr. v. Commissioner of the Div. of Med. Assistance, 439 ...

law.justia.com/cases/federal/appellate-courts/F3/433

433 F.3d - Volume 433 of the Federal Reporter, 3rd Series. Ruben Carnero, Plaintiff, Appellant, v. Boston Scientific Corporation, Defendant, Appellee Date: March 9, 2005. Citation: 433 F.3d 1. United States of America, Appellee, v. Stephen A. Saccoccia, Defendant,jack Hill, Esq., and W. Kenneth O'donnell, Esq., Appellants

massrealestatelawblog.com/tag/monell-v-boston-pads-llc

Jun 3, 2015 ... The Supreme Judicial Court has just released its long awaited opinion in Monell, et al. v. Boston Pads, LLC, (link here), ruling that Massachusetts real estate and rental agents can remain classified as independent contractors under the state's real estate licensing and independent contractor law. The ruling ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC5323428

Feb 24, 2017 ... Cervical dystonia (CD) is the most frequent form of focal dystonia. Symptoms often result in pain and functional disability. Local injections of botulinum neurotoxin are currently the treatment of choice for CD. Although this treatment has proven effective and is widely applied worldwide, many issues still ...

europepmc.org/articles/pmc4833533

Mar 12, 2016 ... While the DSM-V criteria are the gold standard for diagnosis of psychiatric disease, their application requires specific training and is impractical for routine ..... C. G. Goetz has served on Consulting or Advisory Boards with AstraZeneca, Avanir, Boston Scientific, Clearview, Health Advances,, Kanter Health, ...

www.sciencedirect.com/science/article/pii/S0006295213007612

Results of most recent trials are often only available as company press releases and these have been used to update the data in the review by Mangialasche et al .[1] GSI, γ-secretase inhibitor; BSI, β-secretase inhibitor; OLE, open-label extension. It is surprising that this record of failure has not really led to a reconsideration ...

www.mdscongress.org/Congress-2017-Files/PDF/LBASGGPT.pdf

Jun 4, 2017 ... and T2*-mapping (Preibisch and Deichmann 2009, Baudrexel et al. 2009) and real-time 3D ... SN hyperechogenicities were lower as compared to healthy controls at the MABS (MABS vs. controls: median T1 = ..... (Boston Scientific Corporation, Natick, MA) was implanted bilaterally in the STN-SNr. Three of ...

www.alzforum.org/print-series/188276

They did not have a positive result, but we have learned a lot from that trial,” said Joel Menard, who chairs the scientific board that advises the French National .... The drug has been shown to inhibit aggregation of Aβ in transgenic TgCRND8 mice (McLaurin et al., 2006), and based on Phase 2 trial data, the companies ...

www.alzheimersanddementia.com/article/S1552-5260(16)00076-5/fulltext

Mar 14, 2016 ... Almost 30 years later, the progress in our scientific understanding of the neuropathology that precedes clinical symptoms prompted the scientific ..... According to these appreciations, we recommend to disclose or not biomarker status with attention to study type (observational studies vs clinical trials; see ...